An NMR Study of the Bortezomib Degradation under Clinical Use Conditions
Figure 6
HPLC analysis of bortezomib
solutions A, B, and C kept in dark at
for a week. (a) No degradation product was observed. (b) After a month, a
small amount of two new products, eluted at 1 and 5 minutes, respectively, was
recorded.
